(Q41728966)

8 October 2017

1 reference

title

Efficacy and safety of inhaled corticosteroids. New developments (English)

1 reference

8 October 2017

Barnes PJ

1

1 reference

8 October 2017

Pedersen S

series ordinal

2

1 reference

8 October 2017

Busse WW

series ordinal

3

1 reference

8 October 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

American Journal of Respiratory and Critical Care Medicine

8 October 2017

1 reference

8 October 2017

157

1 reference

8 October 2017

S1-53

1 reference

8 October 2017

3 Pt 2

1 reference

Inhaled glucocorticoids for asthma

8 October 2017

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Anti-inflammatory actions of steroids: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Molecular mechanisms of steroid action in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Steroid hormone receptors: many actors in search of a plot

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Regulatory crosstalk at composite response elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Interference of pathway specific transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Allergen-induced oxygen radical release from bronchoalveolar lavage cells and airway hyperresponsiveness in dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Tumour necrosis factor alpha causes retention of activated glucocorticoid receptor within the cytoplasm of A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Mechanisms of action of glucocorticoids in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Lipocortin-1: cellular mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Inhibition of endothelial cell activation by adenovirus-mediated expression of I kappa B alpha, an inhibitor of the transcription factor NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Corticosteroids induce intracellular interleukin-1 receptor antagonist type I expression by a human airway epithelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Enhanced expression of neutral endopeptidase (NEP) in airway epithelium in biopsies from steroid- versus nonsteroid-treated patients with atopic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Nitric oxide and asthmatic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Nitric oxide and lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Nitric oxide and airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Expression of inducible nitric oxide in human lung epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Oxidative stress induces NF kappa B DNA binding and inducible NOS mRNA in human epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of oral prednisone on airway inflammatory mediators in atopic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Increased expression of endothelin in bronchial epithelial cells of asthmatic patients and effect of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Identification of mRNAs associated with programmed cell death in immature thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Glucocorticoid-mediated repression of intercellular adhesion molecule-1 expression in human monocytic and bronchial epithelial cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of an inhaled corticosteroid, budesonide, on alveolar macrophage function in smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Regulation of Human Alveolar Macrophage- and Blood Monocyte-derived Interleukin-8 by Prostaglandin E2 and Dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Characterization of allergen-induced bronchial hyperresponsiveness and airway inflammation in actively sensitized Brown-Norway rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Corticosteroid inhibition of airway microvascular leakage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Pharmacologic control of plasma exudation into tracheobronchial airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Vasocortin: a novel glucocorticoid-induced anti-inflammatory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The epithelium as a target of glucocorticoid action in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Glucocorticoid inhibition of RANTES expression in human lung epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Increased nitric oxide in exhaled air of asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Exhaled nitric oxide: a new lung function test

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Accelerated course of human immunodeficiency virus infection after tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Importance of the inhalation device on the effect of budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 micrograms/day) and budesonide (1600 micrograms/day), for chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

What role for inhaled steroids in chronic asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Comparison of fluticasone propionate and sodium cromoglycate for the treatment of childhood asthma (an open parallel group study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Dissociation of symptom scores and bronchial hyperreactivity: study in asthmatic children on long-term treatment with inhaled beclomethasone dipropionate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A double-blind comparison of inhaled budesonide, long-acting theophylline, and their combination in treatment of nocturnal asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Inhaled budesonide for treatment of recurrent wheezing in early childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Inhaled budesonide for chronic wheezing under 18 months of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of budesonide on pulmonary hyperinflation in young asthmatic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Use of budesonide in severe asthmatics aged 1-3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Prevention of viral induced asthma attacks using inhaled budesonide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The functional response of infants with persistent wheezing to nebulized beclomethasone dipropionate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Nebulised beclomethasone dipropionate in recurrent obstructive episodes after acute bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of budesonide and bambuterol on circadian variation of airway responsiveness and nocturnal symptoms of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch CNSLD Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Acute effect of sodium cromoglycate on airway narrowing induced by 4.5 percent saline aerosol. Outcome before and during treatment with aerosol corticosteroids in patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Airway mucosal inflammation even in patients with newly diagnosed asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The relationship between inflammation and hyperreactivity of the airways in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Asthma and irreversible airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of prednisone and beclomethasone dipropionate on airway responsiveness in asthma: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of 1 year daily treatment with 400 microg budesonide (Pulmicort Turbuhaler) in newly diagnosed asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Mechanism of glucocorticoid action in asthma: too little, too late

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Adverse effects of inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Inhaled corticosteroids in COPD: awaiting controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Failure of Inhaled Corticosteroids to Modify Bronchoconstrictor or Bronchodilator Responsiveness in Middle-Aged Smokers with Mild Airflow Obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflo

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Aerosol beclomethasone in patients with steroid-responsive chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Response to corticosteroids in chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Asthma and allergic rhinitis in the same patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Reduced Allergen-Induced Nasal Congestion and Leukotriene Synthesis with an Orally Active 5-Lipoxygenase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of topical glucocorticoid treatment on nasal mucosal mast cells in allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Early and late nasal symptom response to allergen challenge. The effect of pretreatment with a glucocorticosteroid spray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The clinical efficacy of budesonide in hay fever treatment is dependent on topical nasal application

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Association between pregnancy-induced hypertension and asthma during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Severity of asthma and perinatal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Slow-release theophylline in pregnant asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The cost of childhood asthma to Australian families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The influence of an inhaled steroid on quality of life in patients with asthma or COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Pharmacokinetic optimisation of inhaled steroid therapy in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Acute adrenal insufficiency associated with high dose inhaled steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Knemometry, Urine Cortisol Excretion, and Measures of the Insulin-Like Growth Factor Axis and Collagen Turnover in Children Treated with Inhaled Glucocorticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Suppression of adrenal function in children on inhaled steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Integrated plasma cortisol concentration in children with asthma receiving long‐term inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Bloodspot cortisol in mild asthma: the effect of inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effects of high doses of inhaled corticosteroids on adrenal function in children with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Pathogenesis and treatment of steroid osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Corticosteroids and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Bone turnover in asthmatic children treated with oral prednisolone or inhaled budesonide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The insulin-like growth factor axis and collagen turnover during prednisolone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The insulin-like growth factor axis and collagen turnover in asthmatic children treated with inhaled budesonide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Inhaled corticosteroids, bone formation, and osteocalcin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Beclomethasone inhalation decreases serum osteocalcin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Calcium supplementation and increases in bone mineral density in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Bone mineral density in normal and asthmatic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Cross-sectional study of bone density in asthmatic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Distinctions between short- and long-term human growth studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

On the dynamics of the growth process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Asthma, inhaled corticosteroid treatment, and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Growth of asthmatic children during treatment with budesonide: a double blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Short term linear growth in asthmatic children during treatment with prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Short-term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Growth and the growth hormone axis in prepubertal children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Safety of 1 year of treatment with budesonide in young children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A meta-analysis of the effect of oral and inhaled corticosteroids on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Posterior subcapsular cataract and inhaled corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Use of inhaled corticosteroids and the risk of cataracts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Adrenal function in asthmatic children treated with inhaled budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Assessment of the relative systemic potency of inhaled fluticasone and budesonide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Bone turnover during high dose inhaled corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

21 January 2018

Steroid-resistant asthma

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Glucocorticoid resistance in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Steroid Resistance in Bronchial Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Hypothalamic-pituitary-adrenal axis in corticosteroid-resistant bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Familial and iatrogenic cortisol receptor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Corticosteroid pharmacokinetics in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Steroid-resistant asthma: immunologic and pharmacologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Glucocorticoid therapy for asthma: clinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Resistance to methylprednisolone in cultures of blood mononuclear cells from glucocorticoid-resistant asthmatic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Identification and characterization of a monocyte-derived neutrophil-activating factor in corticosteroid-resistant bronchial asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of corticosteroid treatment on interleukin-1 and tumour necrosis factor secretion by monocytes from subjects with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Glucocorticoid resistance in chronic asthma. Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Cutaneous vasoconstrictor response to glucocorticoids in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The effects of prednisolone on the cutaneous tuberculin response in patients with corticosteroid-resistant bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of a spacer on pulmonary aerosol deposition from a jet nebuliser during mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Tumor-promoting phorbol ester and ras oncogene expression inhibit the glucocorticoid-dependent transcription from the mouse mammary tumor virus long terminal repeat

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Questions about inhaled beta 2-adrenoceptor agonists in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Regular inhaled beta agonist in asthma: effects on exacerbations and lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Role of CBP/P300 in nuclear receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The CBP co-activator is a histone acetyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

The transcriptional coactivators p300 and CBP are histone acetyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Transcriptional control. Sinful repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Molecular dissection of corticosteroid action in the rat hippocampus. Application of the differential display techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Inhaled glucocorticoids: new developments relevant to updating of the asthma management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Lung cancer chemotherapy. Response-survival relationship depends on the method of chest tumor response evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

An economic evaluation of asthma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Pharmacokinetics of intravenous fluticasone propionate in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Systemic activity of inhaled topical steroid in toddlers studied by knemometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

A growing coactivator network

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

Modulation of airway intraepithelial dendritic cells following exposure to steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.3.157315

10.1164/AJRCCM.157.3.157315

21 January 2018

Identifiers

DOI

1 reference

8 October 2017

1 reference